Screening for PsA and Selecting Right Biologic Therapy
Dermatologist and rheumatologist Saakshi Khattri highlights the importance of screening psoriasis patients for psoriatic arthritis and how that may impact treatment decisions.
EP: 1.Choosing the Right Psoriasis Treatment: Tailoring Therapy to Patient Characteristics
EP: 2.Screening for PsA and Selecting Right Biologic Therapy
EP: 3.Biologics for Psoriasis: TNF Blockers
EP: 4.Benefits of IL Therapies in Patients with PP
EP: 5.Understanding Comorbidities: Impact on Biologic Treatment Selection
EP: 6.Unraveling Boxed Warnings: Exploring/Examining Risks in Biologic Treatment Classes
EP: 7.Infectious Diseases and Biologic Treatment Selection
EP: 8.Understanding Biologics for Patients With IBD
EP: 9.Exploring Innovation: Recent Approvals and Novel Approaches to Psoriasis Treatment
EP: 10.Warnings and Precautions for Newer Psoriasis Treatments
EP: 11.When to Switch a Drug Class in Psoriasis Treatment
The focus shifts to the selection of biologic therapies for plaque psoriasis. With a plethora of options available, including TNF blockers, IL-12/23 blockers, IL-17 blockers, and IL-23 blockers, Saakshi Khattri, MD, emphasizes the importance of screening for psoriatic arthritis (PsA) in psoriasis patients. She stresses the need for proactive steps, like asking about joint stiffness or pain to identify symptoms indicative of PsA. Khattri highlights that though the inclination of a dermatologists to refer psoriasis patients with suspected arthritis to rheumatologists, the lengthy wait times for rheumatologist appointments require dermatologists take active steps in identifying and addressing PsA. The consensus is that even a simple inquiry about joint pain can lead to early detection of PsA, which in turn, should influence treatment decisions regarding biologic therapies for psoriasis.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.
